Long-term outcome in polymyositis and dermatomyositis

Area of Science:

• Rheumatology
• Immunology
• Neurology

Background:

• Polymyositis and dermatomyositis are considered treatable, but long-term prognosis and prognostic factors remain poorly understood.
• Existing literature shows wide variations in long-term outcomes and prognostic indicators for these inflammatory myopathies.

Purpose of the Study:

• To analyze prognostic outcome factors in polymyositis and adult dermatomyositis.
• To identify predictors of mortality, clinical outcomes, and disease course in patients with inflammatory myopathies.

Main Methods:

• Determined mortality rates, clinical outcomes (muscle strength, disability, drug use, quality of life), and disease course.
• Analyzed prognostic factors influencing these outcomes in a cohort of 110 patients with a median follow-up of 5 years.

Main Results:

• Disease-related mortality occurred in at least 10% of patients, primarily due to associated cancer and pulmonary complications.
• 80% of patients experienced a polycyclic or chronic continuous disease course; only 20% achieved remission off drugs.
• Muscle weakness was linked to older age (OR 3.6), and disability to male sex (OR 3.1). Jo-1 antibodies predicted persistent drug use (OR 4.4).

Conclusions:

• Inflammatory myopathies like dermatomyositis and polymyositis represent serious conditions with significant disease-related mortality.
• These diseases substantially impact long-term disability and quality of life, even when muscle strength improves.
• Prognostic factors such as age, sex, and specific antibodies (Jo-1) influence patient outcomes and disease management.